[go: up one dir, main page]

US20050255154A1 - Method and composition for treating rhinitis - Google Patents

Method and composition for treating rhinitis Download PDF

Info

Publication number
US20050255154A1
US20050255154A1 US10/842,433 US84243304A US2005255154A1 US 20050255154 A1 US20050255154 A1 US 20050255154A1 US 84243304 A US84243304 A US 84243304A US 2005255154 A1 US2005255154 A1 US 2005255154A1
Authority
US
United States
Prior art keywords
composition
cetirizine
phospholipid
per
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/842,433
Inventor
Lena Pereswetoff-Morath
Anders Carlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolipox AB
Original Assignee
Biolipox AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox AB filed Critical Biolipox AB
Priority to US10/842,433 priority Critical patent/US20050255154A1/en
Assigned to BIOLIPOX AB reassignment BIOLIPOX AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARLSSON, ANDERS, PERESWETOFF-MORATH, LENA
Priority to NZ550412A priority patent/NZ550412A/en
Priority to ZA200608407A priority patent/ZA200608407B/en
Priority to SI200531529T priority patent/SI1771155T1/en
Priority to AT05742190T priority patent/ATE550015T1/en
Priority to ES05742190T priority patent/ES2395130T3/en
Priority to PT05742190T priority patent/PT1771155E/en
Priority to HK07106149.0A priority patent/HK1098960B/en
Priority to CA2536728A priority patent/CA2536728C/en
Priority to US10/571,330 priority patent/US20070026058A1/en
Priority to MXPA06013121A priority patent/MXPA06013121A/en
Priority to CNA2005800153171A priority patent/CN1984643A/en
Priority to BRPI0510778A priority patent/BRPI0510778B8/en
Priority to EA200602092A priority patent/EA014752B1/en
Priority to JP2007512327A priority patent/JP4976283B2/en
Priority to MEP-2012-77A priority patent/ME01436B/en
Priority to PL05742190T priority patent/PL1771155T3/en
Priority to PCT/GB2005/001758 priority patent/WO2005107711A2/en
Priority to AU2005239866A priority patent/AU2005239866B2/en
Priority to RS20120246A priority patent/RS52311B/en
Priority to EP05742190A priority patent/EP1771155B1/en
Priority to CN201310132640.3A priority patent/CN103271910B/en
Priority to HRP20120484TT priority patent/HRP20120484T1/en
Priority to DK05742190.1T priority patent/DK1771155T3/en
Publication of US20050255154A1 publication Critical patent/US20050255154A1/en
Priority to NO20064521A priority patent/NO335840B1/en
Priority to IL179012A priority patent/IL179012A/en
Priority to US13/444,381 priority patent/US9980959B2/en
Priority to CY20121100541T priority patent/CY1112981T1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Definitions

  • the present invention relates to a method for treating rhinitis, and to a corresponding pharmaceutical composition.
  • rhinitis Allergic and non-allergic rhinitis are common disorders affecting about 30% of the population. Rhinitis does have considerable impact on quality of life. In fact, rhinitis is regarded to affect the quality of life, even more so than, e.g., asthma.
  • Hay fever and perennial allergic rhinitis are characterised by sneezing, rhinorrhea, nasal congestion, pruritus, conjunctivitis and pharyngitis.
  • perennial rhinitis chronic nasal obstruction is often prominent and may extend to eustachian tube obstruction.
  • Oral or local antihistamines are first line treatment, and nasal steroids second line treatment for rhinitis.
  • topical corticosteroids and long acting antihistamine agents provide significant relief of symptoms.
  • Antihistamines may also affect non-immunologically (non-IgE) mediated hypersensitivity reactions such as non-allergic rhinitis, exercise induced asthma, cold urticaria, and non-specific bronchial hyperreactivity.
  • Cetirizine dihydrochloride [2- ⁇ 4-[(4-chlorophenyl)-phenylmethyl]-1-piperazinyl- ⁇ ethoxy]acetic acid is an orally and locally active, potent, long acting peripheral histamine H 1 receptor antagonist.
  • Cetirizine is one of the most widely used second generation antihistamines for the treatment of rhino-conjunctivitis and urticaria. It is effective, well tolerated, and safe when used orally in a dose of 10 mg daily. Sedation and dry mouth do however occur as side effects in orally treated patients. Cetirizine is also approved in children for the treatment of rhinitis.
  • antihistamines include reduced sneezing and rhinorrhea, while nasal blockage is less responsive.
  • Local administration of antihistamines (azelastine and levocabastine) has advantages, such as rapid onset of action and fewer side effects.
  • cetirizine dihydrochloride is not an approved medicine for local administration, although it has been administered in that manner in clinical trials.
  • cetirizine presumably as di-hydrochloride
  • Concentrations of 0.625, 1.25, and 2.5 mg/mL of cetirizine were sprayed three times a day for two weeks (Clement P, Roovers M H, Francillon C, Dodion P. Dose - ranging, placebo - controlled study of cetirizine nasal spray in adults with perennial allergic rhinitis. Allergy September 1994; 49(8):668-72).
  • the most common side effects were related to nasal events, though no difference in incidence between the placebo and the cetirizine-treated groups were seen. However, the authors speculate that local irritation had an adverse effect on treatment efficacy.
  • cetirizine nasal spray was found to reduce symptoms and increase nasal peak flow after an allergen challenge.
  • cetirizine mist was administered to the lung with a nebulizer.
  • Ghosh S K De Vos C, McIlroy I, Patel K R. Effect of cetirizine on exercise induced asthma. Thorax April 1991; 46(4):242-4).
  • cetirizine Due to the irritation of the nasal mucosa by cetirizine it is necessary to decrease its immediate exposure of the drug in nasal administration. It has been reported that this can be achieved by providing cetirizine in form of a composition containing cyclodextrin (EP 0 605 203 B1).
  • Still another object of the present invention is to provide a process for the manufacture of this composition.
  • An additional object of the invention is to provide a method for the treatment of rhinitis by nasal administration of cetirizine which lacks at least some of the drawbacks of known methods.
  • the present invention is based on the finding that the presence of liposomes in an aqueous cetirizine solution of a pH at which its zwitterionic form predominates, such as a pH from about pH 4 or pH 5 to about pH 7 and even pH 8, reduces or even eliminates irritation of the nasal mucosa or the ocular mucosa caused by the drug.
  • a pH at which its zwitterionic form predominates such as a pH from about pH 4 or pH 5 to about pH 7 and even pH 8
  • a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from pH 4 to pH 8, preferably from pH 5.0 to pH 7.0, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition from is from 10 or 17 mg to 120 mg per mL, more preferred from 35 mg to 70 mg per mL.
  • any pharmaceutically acceptable salt of cetirizine as well as the zwitterionic form thereof can be used in the invention. Particularly preferred is the use of nitrate salts of cetirizine, most preferred of cetirizine dinitrate.
  • composition of the invention comprises cetirizine or a salt of cetirizine in an amount of from 1 mg/mL to 23 mg/mL calculated on the zwitterionic form, preferably in an amount of from 5.5 mg/mL to 22 mg/mL.
  • composition of the invention can be administered as a nasal spray, nasal drops, and eye drops. It is also possible to administer it as a fine mist to the lungs by nebulization. Irrespective of administration route the irritating properties of cetirizine are reduced by the composition of the invention.
  • Liposomes are well known in the art.
  • a liposome is a structure consisting of one or more concentric spheres of lipid bilayers separated by water or aqueous buffer compartments.
  • Liposomes can be prepared by various methods using solvents, reduced pressure, two-phase systems, freeze drying, sonication etc. described, for instance, in Liposome Drug Delivery Systems, Betageri G V et al., Technomic Publishing AG, Basel, Switzerland, 1993, which is incorporated herein by reference.
  • Liposomes may be based on phospholipids, in particular phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidic acid (PA), phosphatidylserine (PS), or mixtures thereof.
  • PC phosphatidylcholine
  • PG phosphatidylglycerol
  • PI phosphatidylinositol
  • PA phosphatidic acid
  • PS phosphatidylserine
  • the phospholipids of the invention comprise polar and non-polar groups linked to a backbone entity carrying hydroxyl groups, such as glycerol.
  • the phospholipid is of natural origin, preferably membrane phospholipid.
  • the phospholipid is of synthetic or semi-synthetic origin.
  • Phospholipids can be represented by the general formula I wherein R 1 and R 2 independently represent a saturated or unsaturated, branched or straight chain alkyl or alkylene group having 7-23 carbon atoms, preferably 11-19 carbon atoms; and R 3 represents an amide or ester bonding group, such as —CH 2 —CHOH—CH 2 OH (phosphatidylglycerol), —CH 2 —CH 2 —CH 2 —N(CH 3 ) 3 (phosphatidylcholine), —CH 2 —CH 2 —NH 2 (phosphatidylethanolamine), H (phosphatidic acid), —CH 2 —CH(NH 2 )—COOH (phosphatidylserine).
  • R 1 and R 2 independently represent a saturated or unsaturated, branched or straight chain alkyl or alkylene group having 7-23 carbon atoms, preferably 11-19 carbon atoms
  • R 3 represents an amide or ester bonding group, such as —CH 2
  • Particularly preferred phospholipids are those swelling in water, which are capable of spontaneous liposome formation.
  • a phospholipid to form a liposome in excess of water it is necessary that a lamellar liquid crystalline phase is formed, as with phosphatidylcholine (PC).
  • Phosphatidylethanolamine (PE) on the other hand normally favours the reversed hexagonal phase.
  • the phospholipid of the invention does not swell spontaneously in water, it is nevertheless possible to obtain liposomes from it by adding a more polar, swellable phospholipid, such as an anionic phospholipid, preferably phosphatidylglycerol.
  • a more polar, swellable phospholipid such as an anionic phospholipid, preferably phosphatidylglycerol.
  • the liposome formation can be performed at room temperature or any other temperature above 0° C. if the phase transition temperature of the acyl chains (chain melting; gel-to-liquid crystals) is below the freezing point of water, which is the case for natural phospholipids.
  • the polar lipid comprises or, more preferred, consists of glycolipid.
  • glycolipid designates a compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol, a sphingoid or a ceramide (N-acylsphingoid).
  • glycolipid is a glycoglycerolipid.
  • glycoglycerolipid designates a glycolipid containing one or more glycerol residues.
  • glycoglycerolipid comprises or consists of galactoglycerolipid, preferably digalactosyldiacylglycerol of the general formula (II) R 1 and R 2 having the same meaning as in general formula (I).
  • glycolipid is a glycosphingolipid.
  • glycosphingolipid designates lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide.
  • Glycosphingolipid comprises neutral glycophingolipids such as mono- and oligoglycosylsphingoids as well as mono- and oligoglycosylceramides. Most preferred are the respective mono forms.
  • Glycosphingolipid additionally comprises acidic glycosphingolipids such as sialoglycosphingolipids, uronoglycosphingolipids, sulfoglycosphingolipids, phosphoglycosphingolipids, and phosphonoglycosphingolipids.
  • the glycosphingolipid can be ceramide, monohexosylceramide, dihexosylceramide, sphingomyelin, lysosphingomyelin, sphingosine, or mixtures thereof.
  • the glycosphingolipid is sphingomyelin or products derived from sphingomyelin.
  • the sphingomyelin content is preferably established by chromatographic methods.
  • Sphingomyelin can be extracted from milk, preferably bovine milk, brain, egg yolk or erythrocytes from animal blood, preferably sheep.
  • Synthetic and semi-synthetic sphingolipids are comprised by the invention.
  • glycolipid is a glycophosphatidylinositol.
  • glycophosphatidylinositol designates glycolipid which contains saccharides glycosidically linked to the inositol moiety of phosphatidylinositols.
  • composition of the invention may also comprise antioxidant.
  • Antioxidants of the invention comprise alpha tocopherol, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, fumaric acid, malic acid, monothioglycerol, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, potassium metabisulfite, sodium sulfite, tartaric acid, and vitamin E.
  • the buffer of the invention is a pharmaceutically acceptable buffer of any kind that does not interfere with the formation of liposomes, such as a phosphate, citrate, or acetate buffer, and which is capable of maintaining a pH of from about pH 4 to about pH 8 or from about pH 5.0 to about pH 7.0.
  • a chelating agent may be used to reduce the metal ion catalysed oxidation of phospholipid and/or cetirizine.
  • useful chelating agents are ethylenediaminetetraacetic acid (EDTA), ethylenediaminetriacetic acid and diethylenetriaminepentaacetic acid (DTPA). It is also possible to use other agents that protect the composition of the invention and, in particular, possible unsaturated fatty acid residues therein, from oxidation.
  • composition of the invention can comprise one or more preservatives.
  • preservatives for liquid pharmaceutical compositions are benzalkonium chloride, benzoic acid, butylated hydroxyanisole, butylparaben, chlorbutanol, ethylparaben, methylparaben, phenoxyethanol, and phenylethyl alcohol.
  • composition of the invention can also comprise viscosity-increasing agent such as, for instance, hydrophilic polymers like polyethyleneglycol, cellulose derivatives such as hydroxypropylmethyl cellulose.
  • viscosity-increasing agent such as, for instance, hydrophilic polymers like polyethyleneglycol, cellulose derivatives such as hydroxypropylmethyl cellulose.
  • Buffering agents preservatives, viscosity-increasing agents, anti-oxidants, chelating agents and other optional additives will be selected keeping in mind that their detrimental effect on liposome stability should be kept at a minimum. For a given agent this can be ascertained by simple experiments, which are within the reach of a person skilled in the art.
  • the liposome of the invention is prepared by direct swelling of the compound in an aqueous medium without adding any other substances such as stabilizers etc. which are normally required.
  • a process for preparing a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from about pH 4 to about pH 8, preferably from about pH 5.0 to about pH 7.0, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 or 17 mg to 120 mg per mL, more preferred from 35 mg to 70 mg per mL, comprising
  • a preferred aqueous medium is a buffered aqueous solution of cetirizine.
  • Useful buffers are those capable of buffering at a pH within the range from pH 4 to pH 8, more preferred from about pH 5.0 to about pH 7.0, and comprise phosphate buffer, citrate buffer, acetate buffer. The person skilled in the art is aware of the inherent buffering effect of zwitterionic cetirizine.
  • the formation of the liposomes of the invention is facilitated by the spontaneous swelling the polar lipid in water forming a lamellar liquid crystalline phase having a maximum water content of about 35% by weight.
  • a spontaneous formation of liposomes can be obtained when water is added to this lamellar phase. If spontaneous formation is not obtained, the formation of liposomes can be accomplished by mechanical dispersion of the lamellar liquid-crystalline phase in excess water.
  • a preferred dispersion method is vigorous mechanical mixing by, for instance, high speed homogenisation, such as by means of an Ultra Turrax® (Jankel & Kühnke, Germany) homogeniser, but shaking, vortexing and rolling can also be performed.
  • high speed homogenisation such as by means of an Ultra Turrax® (Jankel & Kühnke, Germany) homogeniser, but shaking, vortexing and rolling can also be performed.
  • a homogeneous size distribution of the liposomes of the invention is desirable. It can be obtained by extrusion through a membrane filter, such as one made of polycarbonate, with a pore size of 100 nm. Membrane filters for use in the invention can be procured from Avestin Inc., Canada. A reduced average liposome size and narrowed liposome size distribution is also obtained when the liposomal dispersion is subjected to high-pressure homogenisation with a suitable homogeniser (Rannie A P V, type 7.30 VH, Rannie A S, Denmark) at 500 bar for 4-6 cycles.
  • a suitable homogeniser Rannie A P V, type 7.30 VH, Rannie A S, Denmark
  • composition according to the invention does not normally require conventional treatment with organic solvents such as chloroform or dichloromethane. However, if two or more membrane lipids are used it may be necessary to treat them with organic solvent prior to the addition of the aqueous solvent.
  • a method for treating rhinitis comprising the nasal administration of a pharmacologically effective amount of the composition of the invention to a person suffering from rhinitis.
  • a pharmacologically effective amount of the composition of the invention for nasal administration any state-of-the-art devices suitable for producing sprays of aqueous liposomal dispersions can be used.
  • a corresponding method of treatment according to the invention by ocular administration is also dislosed.
  • the composition of ocular administration is in the form of eye drops.
  • a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising cetirizine and a pharmacologically acceptable liposomal carrier comprising polar lipid dispersed in an aqueous medium with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 mg or 17 mg per mL to 120 mg per mL, more preferred from 35 mg per mL to 70 mg per mL.
  • a buffer solution is prepared by dissolving the buffering agents disodium phosphate dihydrate (Na 2 HPO 4 .2H 2 O) and potassium dihydrogen phosphate (KH 2 PO 4 ) in 1600 ml water (80% of the total batch volume) in a 2000 mL volumetric flask.
  • the weighed amount of active agent is added to the buffer solution and dissolved by stirring with a magnetic stirrer, followed by addition of 100 ml aqueous 1 M sodium hydroxide.
  • the phospholipid is separately weighed and added to the cetirizine solution.
  • Ultrasonication further reduces mean particle size.
  • the vials with the homogenised composition of the invention are placed in an ultrasonication bath and sonicated for 2 ⁇ 10 minutes, whereupon the samples have an almost clear appearance in comparison with the opaque composition afforded by Ultra-Turrax® homogenisation.
  • a buffer solution is prepared by dissolving anhydrous citric acid and solid sodium hydroxide in 160 mL water (80% of the total batch volume) in a 200 mL volumetric flask. The weighed amount of active agent is added and dissolved by stirring with a magnetic stirrer. The phospholipid is separately weighed and added to the cetirizine solution. Stirring is continued until a well dispersed suspension has been formed, the pH of which is adjusted to pH 5.0 ⁇ 0.1 with 1.0 M NaOH and/or 1.0 M HCl. The volume of the preparation is then brought to the final batch volume of 200 mL.
  • the preparation is transferred to a high pressure homogeniser (Rannie A P V, type 7.30 VH, Rannie A S, Denmark) and homogenised at 500-800 bar for 5 cycles. Aliquots of the thus obtained composition of the invention are removed from the collecting vessel and transferred to glass vials.
  • a high pressure homogeniser Rannie A P V, type 7.30 VH, Rannie A S, Denmark
  • Example 4 the particle size reduction method is compared with high speed homogenisation (Ultra Turrax® T25 homogeniser (Jankel & kuhnke, Germany), as described in Example 1.
  • the composition described in this example has been used in both homogenisation methods.
  • Particle size distribution was determined by dynamic light scattering (Zetasizer 4, Malvern Instruments, UK) at an angle of 90° and at room temperature, using a ZET5104 sizing cell and auto:CONTIN analysis mode.
  • Cetirizine dinitrate 11.2 mg Phospholipid (soybean; Lipoid S75; Lipoid GrnbH, 70.0 mg Germany) Disodium phosphate dihydrate; Na 2 HPO 4 .2H 2 O 10.7 mg Potassium dihydrogen phosphate; KH 2 PO 4 5.5 mg 1 M HCl and/or 1 M NaOH To pH 7.0 Water for injection To 1 mL
  • Cetirizin dinitrate 11.1 mg Phospholipid (dioleoylphosphatidylglycerol; DOPG, 35.0 mg Avanti Polar Lipids, AL, USA) Disodium phosphate dihydrate; Na 2 HPO 4 .2H 2 O 10.7 mg Potassium dihydrogen phosphate; KH 2 PO 4 5.5 mg 1 M HCl and/or 1 M sodium hydroxide To pH 7.0 Water for injection To 1 mL
  • Nasal irritation test in a dog model Cetirizine dinitrate (5.6, 11.1 and 22.2 mg/mL, respectively, in the composition of EXAMPLES 1-3; not homogenised) was administered twice daily for 14 days to four male beagle dogs per group (5-6 months old, weighing 10.1-14.2 kg). Clinical signs and body weights were monitored throughout the study. A necropsy was performed, and the nasal cavity was collected and processed (fixated, decalcified and stained with haematoxylin and eosin). Four sections from the nasal cavity were evaluated microscopically, covering squamous, ciliated respiratory, and olfactory epithelium. No treatment-related clinical signs were observed during the administration period. The mean body weight gain over the administration period was unremarkable. The macroscopic and microscopic examination of the nasal cavity and the nasal mucosa preparations did not reveal any signs of mucosal irritation or other change.
  • Ocular irritation test in a rabbit model The potential irritating properties of the phospholipid composition of the invention (EXAMPLE 1-3) was also assessed in an eye irritation test in three white (albino), female New Zealand rabbits per treatment weighing between 2.8 to 3.4 kg. The concentrations investigated were 5.6, 11.1 and 22.2 mg/mL in the composition of EXAMPLE 1. 0.1 mL of the composition was placed in the left eye of each rabbit. The right eye served as untreated control. The eyes were examined prior to treatment and at 1, 24, 48, and 72 h after treatment. The ocular reaction to treatment was graded according to a subjective numerical scoring system.
  • Nasal irritation test A single dose (110 ⁇ L in each nostril) of cetirizine dinitrate (11.1 mg/mL) was administered to five healthy volunteers at four sessions in one of four formulations (I-IV) in each session.
  • Formulations I, II, and III are formulations of the invention whereas reference formulation IV is not a formulation of the invention.
  • the test was performed to investigate the reduction of irritation by liposome formulation as compared to plain buffer solution. Also the influence of particle size and the ratio phospholipid to cetirizine was studied.
  • Nasal symptom score were assessed at 1, 10, 30 minutes post administration.
  • the nasal symptom score included the following variables: nasal congestion, rhinorrhea, itching/sneezing, burning/pain, and taste. These symptoms were qualified by the subjects according to a no—mild—moderate—severe symptom scale (0-3). The results are reported as total score, adding all five subjects scores (maximum score of 15).
  • Nasal irritation test A single dose (110 ⁇ L in each nostril) of cetirizine dinitrate (11.1 mg/mL) was administered to four healthy volunteers at four sessions in one of four formulations (I-IV) in each session. The test was performed to investigate the irritative properties of formulations with different membrane lipids of natural and synthetic origin.
  • Nasal symptom score were assessed at 1, 10, 30 minutes post administration.
  • the nasal symptom score included the following variables: nasal congestion, rhinorrhea, itching/sneezing, burning/pain, and taste. These symptoms were qualified by the subjects according to a no—mild—moderate—severe symptom scale (0-3). The results are reported as total score, adding all four subjects scores (maximum score of 12).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprises zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from pH 4.0 to pH 8.0, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition from is from 10 mg per mL to 120 mg per mL. Also disclosed are methods for its preparation and methods for treating rhinitis by its nasal or ocular administration.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a method for treating rhinitis, and to a corresponding pharmaceutical composition.
    • BACKGROUND OF THE INVENTION
  • Allergic and non-allergic rhinitis are common disorders affecting about 30% of the population. Rhinitis does have considerable impact on quality of life. In fact, rhinitis is regarded to affect the quality of life, even more so than, e.g., asthma.
  • Hay fever and perennial allergic rhinitis are characterised by sneezing, rhinorrhea, nasal congestion, pruritus, conjunctivitis and pharyngitis. In perennial rhinitis, chronic nasal obstruction is often prominent and may extend to eustachian tube obstruction. Oral or local antihistamines are first line treatment, and nasal steroids second line treatment for rhinitis. For most patients, topical corticosteroids and long acting antihistamine agents provide significant relief of symptoms. Antihistamines may also affect non-immunologically (non-IgE) mediated hypersensitivity reactions such as non-allergic rhinitis, exercise induced asthma, cold urticaria, and non-specific bronchial hyperreactivity.
  • Cetirizine dihydrochloride, [2-{4-[(4-chlorophenyl)-phenylmethyl]-1-piperazinyl-}ethoxy]acetic acid is an orally and locally active, potent, long acting peripheral histamine H1 receptor antagonist. Cetirizine is one of the most widely used second generation antihistamines for the treatment of rhino-conjunctivitis and urticaria. It is effective, well tolerated, and safe when used orally in a dose of 10 mg daily. Sedation and dry mouth do however occur as side effects in orally treated patients. Cetirizine is also approved in children for the treatment of rhinitis.
  • The main clinical affects of antihistamines include reduced sneezing and rhinorrhea, while nasal blockage is less responsive. Local administration of antihistamines (azelastine and levocabastine) has advantages, such as rapid onset of action and fewer side effects. At present cetirizine dihydrochloride is not an approved medicine for local administration, although it has been administered in that manner in clinical trials.
  • Some effect was seen on symptoms when cetirizine (presumably as di-hydrochloride) was given as a nasal spray in patients with perennial allergic rhinitis. Concentrations of 0.625, 1.25, and 2.5 mg/mL of cetirizine were sprayed three times a day for two weeks (Clement P, Roovers M H, Francillon C, Dodion P. Dose-ranging, placebo-controlled study of cetirizine nasal spray in adults with perennial allergic rhinitis. Allergy September 1994; 49(8):668-72). The most common side effects were related to nasal events, though no difference in incidence between the placebo and the cetirizine-treated groups were seen. However, the authors speculate that local irritation had an adverse effect on treatment efficacy. In another trial (Francillon C, Pécoud A. Effect of nasal spray of cetirizine in a nasal provocation test with allergen. J Allergy Clin Immunol 1993:91, Suppl 2:258 (abstract)), cetirizine nasal spray was found to reduce symptoms and increase nasal peak flow after an allergen challenge. In exercise-induced asthma, a good protective effect was seen when cetirizine mist was administered to the lung with a nebulizer (Ghosh S K, De Vos C, McIlroy I, Patel K R. Effect of cetirizine on exercise induced asthma. Thorax April 1991; 46(4):242-4).
  • Due to the irritation of the nasal mucosa by cetirizine it is necessary to decrease its immediate exposure of the drug in nasal administration. It has been reported that this can be achieved by providing cetirizine in form of a composition containing cyclodextrin (EP 0 605 203 B1).
  • The lipophilicity behaviour of the cationic (anion: chloride), zwitterionic, and anionic forms of cetirizine in buffered aqueous phosphatidylcholine liposome systems containing from about 1 to 33.5 mg/mL of phospholipid has been studied (Plemper van Balen G et al. Lipophilicity behaviour of the zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems. Pharm. Res. 2001; 18:694-701. The aim with the study was to gain insight into the mechanism of interaction of the various electrical species of cetirizine with membranes. In respect of the cationic species, both hydrophobic and electrostatic interactions were found to be involved. The authors consider the zitterionic form of cetirizine, which dominates in the pH range of from about pH 4 to about pH 7, and even from about pH 3 to about pH 8, to be prevented from entry into the liposomal membrane by rendering the formation of lipophilic folded conformers of cetirizine more difficult.
    • OBJECTS OF THE INVENTION
  • It is an object of the present invention to provide a pharmaceutical composition for nasal administration of cetirizine that protects the nasal mucosa from irritation by the active agent.
  • It is another object of the present invention to provide a pharmaceutical composition for ocular administration of cetirizine that protects the ocular mucosa from irritation by the active agent.
  • Still another object of the present invention is to provide a process for the manufacture of this composition.
  • An additional object of the invention is to provide a method for the treatment of rhinitis by nasal administration of cetirizine which lacks at least some of the drawbacks of known methods.
  • Further object of the invention will become apparent from the study of the following summary of the invention, the description of preferred embodiments thereof, and the appended claims.
    • SUMMARY OF THE INVENTION
  • The present invention is based on the finding that the presence of liposomes in an aqueous cetirizine solution of a pH at which its zwitterionic form predominates, such as a pH from about pH 4 or pH 5 to about pH 7 and even pH 8, reduces or even eliminates irritation of the nasal mucosa or the ocular mucosa caused by the drug.
  • According to the present invention is disclosed a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from pH 4 to pH 8, preferably from pH 5.0 to pH 7.0, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition from is from 10 or 17 mg to 120 mg per mL, more preferred from 35 mg to 70 mg per mL.
  • Any pharmaceutically acceptable salt of cetirizine as well as the zwitterionic form thereof can be used in the invention. Particularly preferred is the use of nitrate salts of cetirizine, most preferred of cetirizine dinitrate.
  • It is preferred for the composition of the invention to comprise cetirizine or a salt of cetirizine in an amount of from 1 mg/mL to 23 mg/mL calculated on the zwitterionic form, preferably in an amount of from 5.5 mg/mL to 22 mg/mL.
  • The composition of the invention can be administered as a nasal spray, nasal drops, and eye drops. It is also possible to administer it as a fine mist to the lungs by nebulization. Irrespective of administration route the irritating properties of cetirizine are reduced by the composition of the invention.
  • Liposomes are well known in the art. A liposome is a structure consisting of one or more concentric spheres of lipid bilayers separated by water or aqueous buffer compartments.
  • Numerous patents and scientific papers on liposomes have been published and the technical field of applying various lipid derivatives in combination with amphiphatic compounds such as phospholipids are well known to those skilled in the art. Liposomes can be prepared by various methods using solvents, reduced pressure, two-phase systems, freeze drying, sonication etc. described, for instance, in Liposome Drug Delivery Systems, Betageri G V et al., Technomic Publishing AG, Basel, Switzerland, 1993, which is incorporated herein by reference.
  • Liposomes may be based on phospholipids, in particular phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidic acid (PA), phosphatidylserine (PS), or mixtures thereof.
  • The phospholipids of the invention comprise polar and non-polar groups linked to a backbone entity carrying hydroxyl groups, such as glycerol. According to a preferred embodiment of the invention the phospholipid is of natural origin, preferably membrane phospholipid. According to another preferred embodiment of the invention the phospholipid is of synthetic or semi-synthetic origin.
  • Phospholipids can be represented by the general formula I
    Figure US20050255154A1-20051117-C00001
    wherein R1 and R2 independently represent a saturated or unsaturated, branched or straight chain alkyl or alkylene group having 7-23 carbon atoms, preferably 11-19 carbon atoms; and R3 represents an amide or ester bonding group, such as —CH2—CHOH—CH2OH (phosphatidylglycerol), —CH2—CH2—CH2—N(CH3)3 (phosphatidylcholine), —CH2—CH2—NH2 (phosphatidylethanolamine), H (phosphatidic acid), —CH2—CH(NH2)—COOH (phosphatidylserine).
  • Particularly preferred phospholipids are those swelling in water, which are capable of spontaneous liposome formation. For a phospholipid to form a liposome in excess of water it is necessary that a lamellar liquid crystalline phase is formed, as with phosphatidylcholine (PC). Phosphatidylethanolamine (PE) on the other hand normally favours the reversed hexagonal phase.
  • If the phospholipid of the invention does not swell spontaneously in water, it is nevertheless possible to obtain liposomes from it by adding a more polar, swellable phospholipid, such as an anionic phospholipid, preferably phosphatidylglycerol.
  • The liposome formation can be performed at room temperature or any other temperature above 0° C. if the phase transition temperature of the acyl chains (chain melting; gel-to-liquid crystals) is below the freezing point of water, which is the case for natural phospholipids.
  • According to a first preferred aspect of the invention the polar lipid comprises or, more preferred, consists of glycolipid. In this application, the term glycolipid designates a compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol, a sphingoid or a ceramide (N-acylsphingoid).
  • According to a second preferred aspect of the invention glycolipid is a glycoglycerolipid. In this application the term glycoglycerolipid designates a glycolipid containing one or more glycerol residues. According to a particularly preferred aspect of the invention glycoglycerolipid comprises or consists of galactoglycerolipid, preferably digalactosyldiacylglycerol of the general formula (II)
    Figure US20050255154A1-20051117-C00002
    R1 and R2 having the same meaning as in general formula (I).
  • According to a third preferred aspect of the invention glycolipid is a glycosphingolipid. In this application the term glycosphingolipid designates lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide. Glycosphingolipid comprises neutral glycophingolipids such as mono- and oligoglycosylsphingoids as well as mono- and oligoglycosylceramides. Most preferred are the respective mono forms. Glycosphingolipid additionally comprises acidic glycosphingolipids such as sialoglycosphingolipids, uronoglycosphingolipids, sulfoglycosphingolipids, phosphoglycosphingolipids, and phosphonoglycosphingolipids. The glycosphingolipid can be ceramide, monohexosylceramide, dihexosylceramide, sphingomyelin, lysosphingomyelin, sphingosine, or mixtures thereof. Preferably the glycosphingolipid is sphingomyelin or products derived from sphingomyelin. The sphingomyelin content is preferably established by chromatographic methods. Sphingomyelin can be extracted from milk, preferably bovine milk, brain, egg yolk or erythrocytes from animal blood, preferably sheep. Synthetic and semi-synthetic sphingolipids are comprised by the invention.
  • According to a fourth preferred aspect of the invention glycolipid is a glycophosphatidylinositol. In this application the term glycophosphatidylinositol designates glycolipid which contains saccharides glycosidically linked to the inositol moiety of phosphatidylinositols.
  • The composition of the invention may also comprise antioxidant. Antioxidants of the invention comprise alpha tocopherol, ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, fumaric acid, malic acid, monothioglycerol, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, potassium metabisulfite, sodium sulfite, tartaric acid, and vitamin E.
  • The buffer of the invention is a pharmaceutically acceptable buffer of any kind that does not interfere with the formation of liposomes, such as a phosphate, citrate, or acetate buffer, and which is capable of maintaining a pH of from about pH 4 to about pH 8 or from about pH 5.0 to about pH 7.0.
  • According to the invention a chelating agent may be used to reduce the metal ion catalysed oxidation of phospholipid and/or cetirizine. Examples of useful chelating agents are ethylenediaminetetraacetic acid (EDTA), ethylenediaminetriacetic acid and diethylenetriaminepentaacetic acid (DTPA). It is also possible to use other agents that protect the composition of the invention and, in particular, possible unsaturated fatty acid residues therein, from oxidation.
  • The composition of the invention can comprise one or more preservatives. Examples of common preservatives for liquid pharmaceutical compositions are benzalkonium chloride, benzoic acid, butylated hydroxyanisole, butylparaben, chlorbutanol, ethylparaben, methylparaben, phenoxyethanol, and phenylethyl alcohol.
  • To retain the composition of the invention at its application site it can also comprise viscosity-increasing agent such as, for instance, hydrophilic polymers like polyethyleneglycol, cellulose derivatives such as hydroxypropylmethyl cellulose.
  • Buffering agents, preservatives, viscosity-increasing agents, anti-oxidants, chelating agents and other optional additives will be selected keeping in mind that their detrimental effect on liposome stability should be kept at a minimum. For a given agent this can be ascertained by simple experiments, which are within the reach of a person skilled in the art.
  • According to the invention is also disclosed a process for preparing a composition of the aforementioned kind. Preferably the liposome of the invention is prepared by direct swelling of the compound in an aqueous medium without adding any other substances such as stabilizers etc. which are normally required.
  • In particular, according to the present invention, is disclosed a process for preparing a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from about pH 4 to about pH 8, preferably from about pH 5.0 to about pH 7.0, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 or 17 mg to 120 mg per mL, more preferred from 35 mg to 70 mg per mL, comprising
      • (a) providing a polar lipid or a mixture of polar lipids that is swellable in aqueous media;
      • (b) providing an aqueous solution of cetirizine and buffer having a pH of from pH 4 to pH 8;
      • (c) adding the polar lipid to the aqueous solution while stirring, thereby forming a cetirizine liposome preparation;
      • (d) optionally adjusting the pH of the preparation to a desired value within the range of from pH 4 to pH 8 by adding an acid or a base;
      • (e) optionally adding water or saline to the preparation to obtain a desired final batch volume;
      • (f) homogenising the preparation to obtain said pharmaceutical composition.
  • A preferred aqueous medium is a buffered aqueous solution of cetirizine. Useful buffers are those capable of buffering at a pH within the range from pH 4 to pH 8, more preferred from about pH 5.0 to about pH 7.0, and comprise phosphate buffer, citrate buffer, acetate buffer. The person skilled in the art is aware of the inherent buffering effect of zwitterionic cetirizine.
  • The formation of the liposomes of the invention is facilitated by the spontaneous swelling the polar lipid in water forming a lamellar liquid crystalline phase having a maximum water content of about 35% by weight. Depending on the lipid or lipid mixture used and the other conditions a spontaneous formation of liposomes can be obtained when water is added to this lamellar phase. If spontaneous formation is not obtained, the formation of liposomes can be accomplished by mechanical dispersion of the lamellar liquid-crystalline phase in excess water.
  • A preferred dispersion method is vigorous mechanical mixing by, for instance, high speed homogenisation, such as by means of an Ultra Turrax® (Jankel & Kühnke, Germany) homogeniser, but shaking, vortexing and rolling can also be performed.
  • A homogeneous size distribution of the liposomes of the invention is desirable. It can be obtained by extrusion through a membrane filter, such as one made of polycarbonate, with a pore size of 100 nm. Membrane filters for use in the invention can be procured from Avestin Inc., Canada. A reduced average liposome size and narrowed liposome size distribution is also obtained when the liposomal dispersion is subjected to high-pressure homogenisation with a suitable homogeniser (Rannie A P V, type 7.30 VH, Rannie A S, Denmark) at 500 bar for 4-6 cycles.
  • Surprisingly it was found that the presence of cetirizine in a liposome vehicle resulted in a reduction of liposome size. Smaller liposomes are generally more stable physically and, due to their higher surface/volume ratio, easier resorbed by the mucosa.
  • The preparation of the composition according to the invention does not normally require conventional treatment with organic solvents such as chloroform or dichloromethane. However, if two or more membrane lipids are used it may be necessary to treat them with organic solvent prior to the addition of the aqueous solvent.
  • According to the present invention is also disclosed a method for treating rhinitis comprising the nasal administration of a pharmacologically effective amount of the composition of the invention to a person suffering from rhinitis. For nasal administration any state-of-the-art devices suitable for producing sprays of aqueous liposomal dispersions can be used. It is also possible to administer the composition of the invention by nasal drops and even by inhalation of cetirizine liposome mist from a nebulizer. A corresponding method of treatment according to the invention by ocular administration is also dislosed. Preferably the composition of ocular administration is in the form of eye drops.
  • According to the present invention is furthermore disclosed a method for the manufacture of a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising cetirizine and a pharmacologically acceptable liposomal carrier comprising polar lipid dispersed in an aqueous medium with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 mg or 17 mg per mL to 120 mg per mL, more preferred from 35 mg per mL to 70 mg per mL.
  • In the following the invention will be explained in more detail by reference to a number of preferred embodiments.
    • DESCRIPTION OF PREFERRED EMBODIMENTS MANUFACTURE OF EXEMPLARY COMPOSITIONS OF THE INVENTION (EXAMPLES 1-4) EXAMPLE 1
  • TABLE 1
    Batch formula of the composition of the invention
    Cetirizine dinitrate* 22.2 g
    Phospholipid (from soybean**) 70.0 g
    Disodium phosphate dihydrate; Na2HPO4.2H2O 21.3 g
    Potassium dihydrogenphosphate; KH2PO4 11.0 g
    1 M Hydrochloric acid and/or 1 M sodium hydroxide to pH 7.0
    Water for injection to 2.0 L

    *White solid, crystallized from THF/acetonitrile/water 2:1:0.28. Obtained from commercially available cetirizine dihydrochloride via neutralisation of the free base with nitric acid.

    **Lipoid S75, Lipoid GmbH, Germany
  • General procedure. For weights and volumes reference is made to Table 1. A buffer solution is prepared by dissolving the buffering agents disodium phosphate dihydrate (Na2HPO4.2H2O) and potassium dihydrogen phosphate (KH2PO4) in 1600 ml water (80% of the total batch volume) in a 2000 mL volumetric flask. The weighed amount of active agent is added to the buffer solution and dissolved by stirring with a magnetic stirrer, followed by addition of 100 ml aqueous 1 M sodium hydroxide. The phospholipid is separately weighed and added to the cetirizine solution. Stirring is continued until a well dispersed suspension has been formed, the pH of which is adjusted to pH 7.0±0.1 with 1.0 M NaOH or 1.0 M HCl. The volume of the preparation is then brought to the final batch volume of 2000 mL. The preparation is transferred to a 5 L glass vessel provided with an Ultra Turrax® T25 homogeniser (Jankel & Kühnke, Germany). Homogenisation is carried out at 22000 rpm for 3×2 minutes interrupted by 10 min settling periods. 10 mL aliquots of the thus obtained composition of the invention are removed from the stirred dispersion and transferred to glass vials onto which spray heads (VP7 or VP7D; Valois S. A., France) are either crimped on or attached by screw fitting after filling. The stirred composition as well as the composition aliquots in the vials is protected from light.
  • Ultrasonication. Ultrasonication further reduces mean particle size. In this method the vials with the homogenised composition of the invention are placed in an ultrasonication bath and sonicated for 2×10 minutes, whereupon the samples have an almost clear appearance in comparison with the opaque composition afforded by Ultra-Turrax® homogenisation.
  • The aforementioned particle size reduction methods are compared in Table 2. Particle size distribution was determined by laser diffraction (Mastersizer 2000, Malvern Instrument, UK). A Fraunhofer theory based method was used to calculate the particle size of the high speed homogenised sample whereas a MIE (2.50/0.001) theory based method was used for calculation of the particle size of the sample additionally subjected to sonication.
    TABLE 2
    Particle size reduction (composition of the invention)
    Treatment Average size (nm)
    High speed homogenisation 940
    High speed homogenisation + 162
    ultrasonication
    • EXAMPLE 2
  • TABLE 3
    Batch formula of the composition of the invention
    Cetirizine dinitrate 2.22 mg
    Phospholipid (soybean; Lipoid S75; 7.00 mg
    Lipoid GmbH, Germany)
    Citric acid, anhydrous 3.84 mg
    Sodium hydroxide, solid 1.67 mg
    Ascorbic acid 0.20 mg
    EDTA sodium 0.20 mg
    HCl, 1 M and/or NaOH, 1 M To pH 5.0
    Water for injection To 200 mL
  • General procedure. For weights and volumes reference is made to Table 3. A buffer solution is prepared by dissolving anhydrous citric acid and solid sodium hydroxide in 160 mL water (80% of the total batch volume) in a 200 mL volumetric flask. The weighed amount of active agent is added and dissolved by stirring with a magnetic stirrer. The phospholipid is separately weighed and added to the cetirizine solution. Stirring is continued until a well dispersed suspension has been formed, the pH of which is adjusted to pH 5.0±0.1 with 1.0 M NaOH and/or 1.0 M HCl. The volume of the preparation is then brought to the final batch volume of 200 mL. The preparation is transferred to a high pressure homogeniser (Rannie A P V, type 7.30 VH, Rannie A S, Denmark) and homogenised at 500-800 bar for 5 cycles. Aliquots of the thus obtained composition of the invention are removed from the collecting vessel and transferred to glass vials.
  • In Table 4 the particle size reduction method is compared with high speed homogenisation (Ultra Turrax® T25 homogeniser (Jankel & Kühnke, Germany), as described in Example 1. The composition described in this example has been used in both homogenisation methods. Particle size distribution was determined by dynamic light scattering (Zetasizer 4, Malvern Instruments, UK) at an angle of 90° and at room temperature, using a ZET5104 sizing cell and auto:CONTIN analysis mode.
    TABLE 4
    Particle size reduction (composition of the invention)
    Cetirizine Z average
    Treatment (mg/mL) mean (nm)
    High speed homogenisation 11.1 282
    High pressure homogenisation at 500 bar 11.1 77
    High pressure homogenisation at 800 bar 11.1 50
    High pressure homogenisation at 500 bar 0 130
    High pressure homogenisation at 800 bar 0 121
  • The methods used for preparing these exemplary batch compositions were adapted for preparing the following additional compositions of the invention.
    • EXAMPLE 3
  • TABLE 5
    Composition of the invention
    Cetirizine dinitrate 5.6 mg
    Phospholipid (soybean; Lipoid S75; Lipoid GmbH, 35.0 mg
    Germany)
    Disodium phosphate dihydrate; Na2HPO4.2H2O 10.7 mg
    Potassium dihydrogen phosphate; KH2PO4 5.5 mg
    1 M HCl and/or 1 M NaOH To pH 7.0
    Water for injection To 1 mL
    • EXAMPLE 4
  • TABLE 6
    Composition of the invention
    Cetirizine dinitrate 22.2 mg
    Phospholipid (soybean; Lipoid S75; 35.0 mg
    Lipoid GmbH, Germany)
    Disodium phosphate dihydrate; Na2HPO4.2H2O 10.7 mg
    Potassium dihydroqen phosphate; KH2PO4 5.5 mg
    1 M HCl and/or 1 M NaOH To pH 7.0
    Water for injection To 1 mL
    • EXAMPLE 5
  • TABLE 7
    Composition of the invention
    Cetirizine dinitrate 11.2 mg
    Phospholipid (soybean; Lipoid S75; Lipoid GrnbH, 70.0 mg
    Germany)
    Disodium phosphate dihydrate; Na2HPO4.2H2O 10.7 mg
    Potassium dihydrogen phosphate; KH2PO4 5.5 mg
    1 M HCl and/or 1 M NaOH To pH 7.0
    Water for injection To 1 mL
    • EXAMPLE 6
  • TABLE 8
    Composition of the invention
    Cetirizine dinitrate 11.1 mg
    Phospholipid (dioleoylphoshatidylcholine; DOPC, 35.0
    Larodan Fine Chemicals, Sweden)
    Disodium phosphate dihydrate; Na2HPO4.2H2O 10.7
    Potassium dihydrogen phosphate; KH2PO4 5.5
    1 M HCl and/or 1 M sodium hydroxide To pH 7.0
    Water for injection To 1 mL
    • EXAMPLE 7
  • TABLE 9
    Composition of the invention
    Cetirizin dinitrate 11.1 mg
    Phospholipid (dioleoylphosphatidylglycerol; DOPG, 35.0 mg
    Avanti Polar Lipids, AL, USA)
    Disodium phosphate dihydrate; Na2HPO4.2H2O 10.7 mg
    Potassium dihydrogen phosphate; KH2PO4 5.5 mg
    1 M HCl and/or 1 M sodium hydroxide To pH 7.0
    Water for injection To 1 mL
    • EXAMPLE 8
  • TABLE 10
    Composition of the invention
    Cetirizine dinitrate 11.1 mg
    Galactolipid (digalactosyldiacylglycerol; DGDG, 35.0 mg
    Larodan Fine Chemicals, Sweden)
    Disodium phosphate dihydrate; Na2HPO4.2H2O 10.7 mg
    Potassium dihydrogen phosphate; KH2PO4 5.5 mg
    1 M HCl and/or 1 M sodium hydroxide To pH 7.0
    Water for injection To 1 mL
    • EXAMPLE 9
  • Nasal irritation test in a dog model. Cetirizine dinitrate (5.6, 11.1 and 22.2 mg/mL, respectively, in the composition of EXAMPLES 1-3; not homogenised) was administered twice daily for 14 days to four male beagle dogs per group (5-6 months old, weighing 10.1-14.2 kg). Clinical signs and body weights were monitored throughout the study. A necropsy was performed, and the nasal cavity was collected and processed (fixated, decalcified and stained with haematoxylin and eosin). Four sections from the nasal cavity were evaluated microscopically, covering squamous, ciliated respiratory, and olfactory epithelium. No treatment-related clinical signs were observed during the administration period. The mean body weight gain over the administration period was unremarkable. The macroscopic and microscopic examination of the nasal cavity and the nasal mucosa preparations did not reveal any signs of mucosal irritation or other change.
    • EXAMPLE 10
  • Ocular irritation test in a rabbit model. The potential irritating properties of the phospholipid composition of the invention (EXAMPLE 1-3) was also assessed in an eye irritation test in three white (albino), female New Zealand rabbits per treatment weighing between 2.8 to 3.4 kg. The concentrations investigated were 5.6, 11.1 and 22.2 mg/mL in the composition of EXAMPLE 1. 0.1 mL of the composition was placed in the left eye of each rabbit. The right eye served as untreated control. The eyes were examined prior to treatment and at 1, 24, 48, and 72 h after treatment. The ocular reaction to treatment was graded according to a subjective numerical scoring system. Signs of conjunctival irritation (redness) were observed in two rabbits in the group receiving the composition containing 22.2 mg/mL cetirizine dinitrate. In the first rabbit a score 2 (diffuse, crimson colour, individual vessels not easily discernable) on a scale graded 0-3 was noted one hour after treatment. In the second rabbit a score 1 (some hyperaemic blood vessels) on a four grade scale was noted at 24 h. In both cases the redness was not present at subsequent observations, and was thus considered reversible. No other signs of eye irritation were observed in any of the animals.
    • EXAMPLE 11
  • Nasal irritation test. A single dose (110 μL in each nostril) of cetirizine dinitrate (11.1 mg/mL) was administered to five healthy volunteers at four sessions in one of four formulations (I-IV) in each session. Formulations I, II, and III are formulations of the invention whereas reference formulation IV is not a formulation of the invention. The test was performed to investigate the reduction of irritation by liposome formulation as compared to plain buffer solution. Also the influence of particle size and the ratio phospholipid to cetirizine was studied.
    TABLE 11
    Cetirizine dinitrate formulations used in testing nasal
    irritation
    mg
    Phospholipid
    Features per
    Formulation Composition mL Vehicle Features
    I EXAMPLE 1 35 High speed homogenised
    II EXAMPLE 1 35 High speed homogenised +
    ultrasonicated
    III EXAMPLE 5 70 High speed homogenised +
    ultrasonicated
    IV Reference nil; Plain buffered aqueous
    phosphate solution
    buffer
  • Nasal symptom score were assessed at 1, 10, 30 minutes post administration. The nasal symptom score included the following variables: nasal congestion, rhinorrhea, itching/sneezing, burning/pain, and taste. These symptoms were qualified by the subjects according to a no—mild—moderate—severe symptom scale (0-3). The results are reported as total score, adding all five subjects scores (maximum score of 15).
  • The phospholipid formulations were better tolerated than the plain buffer solution. Smaller liposomes seem to be of advantage. The mild discomfort reported by all subjects at 1 minute had practically disappeared at 10 min for the two formulations (II and III) that had reduced particle size by sonication. In contrast, the initial mild discomfort reported for formulation I persisted at 10 minutes. Increasing the ratio of phospholipid to cetirizine did not further improve the performance of the formulation.
    TABLE 12
    Nasal irritation test in healthy volunteers.
    Formu- Con- Itching/ Burning/ TOTAL
    lation gestion Rhinorrhea sneezing Pain Taste SCORE
    1 min Post Administration
    I 0 3 1 6.5 1 11.5
    II 0 1 1 6.0 0 8
    III 0 0 1 5.5 0 6.5
    IV 0 6 2 14.5 2 24.5
    10 min Post Administration
    I 0 1 1 6 4 12
    II 0 0 0 2 2 4
    III 0 0 1 1 4.5 6.5
    IV 0 1 1 8 3 13
    30 min Post Administration
    I 0 0 1 1 3 5
    II 0 0 1 0 0 1
    III 0 0 0 1 0 1
    IV 0 0 0 1.5 1 2.5
    • EXAMPLE 12
  • Nasal irritation test. A single dose (110 μL in each nostril) of cetirizine dinitrate (11.1 mg/mL) was administered to four healthy volunteers at four sessions in one of four formulations (I-IV) in each session. The test was performed to investigate the irritative properties of formulations with different membrane lipids of natural and synthetic origin.
    TABLE 13
    Cetirizine dinitrate formulations used in testing nasal
    irritation
    Formulation Composition Membrane lipid
    I EXAMPLE 1 Lipoid S75 Natural
    II EXAMPLE 6 Dioleoylphoshatidylcholine Synthetic
    (DOPC)
    III EXAMPLE 7 Dioleoylphoshatidylglycerol Synthetic
    (DOPG)
    IV EXAMPLE 8 Digalactosyldiacylglycerol Natural
    (DGDG)
  • Nasal symptom score were assessed at 1, 10, 30 minutes post administration. The nasal symptom score included the following variables: nasal congestion, rhinorrhea, itching/sneezing, burning/pain, and taste. These symptoms were qualified by the subjects according to a no—mild—moderate—severe symptom scale (0-3). The results are reported as total score, adding all four subjects scores (maximum score of 12).
  • The formulations containing DOPC and DOPG were very well tolerated with practically no reports of any kind at 1 minute. At 10 minutes there is still a tendency of better tolerability of these two formulations as compared to the membrane lipids of natural origin.
    TABLE 14
    Nasal irritation test in healthy volunteers.
    Formu- Con- Itching/ Burning/ TOTAL
    lation gestion Rhinorrhea sneezing Pain Taste SCORE
    1 min Post Administration
    I 0 1 1 3 2 7
    II 0 1 0 1 0 2
    III 1 0 1 0 0 1
    IV 0 1.5 2 2 4 9.5
    10 min Post Administration
    I 0 1 0 2 3 6
    II 0 0 0 1 2 3
    III 0 0.5 0.5 1 2 4
    IV 0.5 0.5 0 1 4 6
    30 min Post Administration
    I 1 0 0 0 0 1
    II 0 0 0 0 0 0
    III 0 0 1 0 1 2
    IV 0 0 0 0 0 0

Claims (35)

1. Pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from pH 4.0 to pH 8.0, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 mg per mL to 120 mg per mL.
2. The composition of claim 1, wherein the amount of phospholipid is from 17 mg per mL to 120 mg per mL.
3. The composition of claim 1, wherein the amount of phospholipid is from 35 mg per mL to 70 mg per mL.
4. The composition of claim 1, wherein said pH is from 5.0 to 7.0.
5. The composition of claim 1, wherein the zwitterionic cetirizine has been obtained from a chloride or nitrate salt of cetirizine.
6. The composition of claim 5, wherein the salt is cetirizine dinitrate.
7. The composition of claim 1, wherein the buffer is selected from phosphate buffer, citrate buffer, acetate buffer.
8. The composition of claim 1 comprising cetirizine or a salt of cetirizine in an amount of from 1 mg/mL to 23 mg/mL calculated on the zwitterionic form.
9. The composition of claim 1, comprising cetirizine or a salt of cetirizine in an amount of from 5.5 mg/mL to 22 mg/mL.
10. The composition of claim 1 wherein the liposome is based on a phospholipid or on a mixture of phospholipids.
11. The composition of claim 10, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol, phosphatidic acid, and phosphatidylserine
12. The composition of claim 10, wherein at least one phospholipid is of natural origin.
13. The composition of claim 10, wherein at least one phospholipid is of synthetic or semi-synthetic origin.
14. The composition of claim 1, wherein the liposome is based on a glycolipid or a mixture of glycolipids.
15. The composition of claim 1, wherein the liposome consists of a glycolipid or a mixture of glycolipids.
16. The composition of claim 14, where the glycolipid is glycoglycerolipid.
17. The composition of claim 16, wherein the glycoglycerolipid comprises galactoglycerolipid.
18. The composition of claim 16, wherein glycoglycerolipid comprises digalactosyldiacylglycerol.
19. The composition of claim 18, wherein glycoglycerolipid substantially consists of digalactosyldiacylglycerol.
20. The composition of claim 14, wherein the glycolipid is a glycosphingolipid.
21. The composition of claim 14, wherein the glycolipid is a glycophosphatidylinositol.
22. The composition of claim 1 comprising at least one antioxidant, chelating agent, preservative, or viscosity-increasing agent.
23. A process for preparing a pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, polar lipid liposome, a pharmaceutical acceptable aqueous carrier and, optionally, a pharmaceutically acceptable buffer capable of providing a pH of from about pH 4 to about pH 8, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 to 120 mg per mL, comprising
(a) providing a polar lipid or a mixture of polar lipids that is swellable in aqueous media;
(b) providing an aqueous solution of cetirizine and buffer having a pH of from pH 4 to pH 8;
(c) adding the polar lipid to the aqueous solution while stirring, thereby forming a cetirizine liposome preparation;
(d) optionally adjusting the pH of the preparation to a desired value within the range of from pH 4 to pH 8 by adding an acid or a base;
(e) optionally adding water or saline or a buffer having a pH of from pH 4 to pH 8 to the preparation to obtain a desired final batch volume;
(f) homogenising the preparation to obtain said pharmaceutical composition.
24. The process of claim 23, wherein the amount of phospholipid in the composition is from 17 to 120 mg per mL.
25. The process of claim 23, wherein the amount of phosphlipid in the composition is from 35 mg to 70 mg per mL.
26. The process of claim 23, wherein the pH is from from pH 5.0 to pH 7.0.
27. The process of claim 23, wherein said mixture of swellable polar lipids has be pre-treated with organic solvent.
28. The process of claim 23, wherein homogenisation comprises at least one of vigorous mechanical mixing, shaking, vortexing, or rolling.
29. The process of claim 22, additional comprising reduction of liposome size.
30. The process of claim 29, wherein the reduction of liposome size comprises extrusion through a membrane filter or high-pressure homogenization or both.
31. A method for the manufacture of a pharmaceutical composition for the treatment of rhinitis comprising combining cetirizine and a pharmacologically acceptable liposomal carrier comprising polar lipid dispersed in an aqueous medium, with the proviso that, if the polar lipid comprises phospholipid, the amount of phospholipid in the composition is from 10 mg to 120 mg per mL.
32. The method of claim 31, wherein the polar lipid is glycoglycerolipid.
33. The method of claim 32, wherein the glycoglycerolipid comprises galactoglycerolipid.
34. A method of treating rhinitis comprising nasal administration of a pharmacologically effective amount of the composition of claim 1.
35. A method of treating rhinitis comprising ocular administration of a pharmacologically effective amount of the composition claim 1.
US10/842,433 2004-05-11 2004-05-11 Method and composition for treating rhinitis Abandoned US20050255154A1 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
US10/842,433 US20050255154A1 (en) 2004-05-11 2004-05-11 Method and composition for treating rhinitis
DK05742190.1T DK1771155T3 (en) 2004-05-11 2005-05-06 Method and composition for the treatment of rhinitis
JP2007512327A JP4976283B2 (en) 2004-05-11 2005-05-06 Method and composition for treatment of rhinitis
MEP-2012-77A ME01436B (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
SI200531529T SI1771155T1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
AT05742190T ATE550015T1 (en) 2004-05-11 2005-05-06 METHOD AND COMPOSITION FOR TREATING RHINITIS
ES05742190T ES2395130T3 (en) 2004-05-11 2005-05-06 Method and composition for the treatment of rhinitis
PT05742190T PT1771155E (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
HK07106149.0A HK1098960B (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
CA2536728A CA2536728C (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
US10/571,330 US20070026058A1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
MXPA06013121A MXPA06013121A (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis.
CNA2005800153171A CN1984643A (en) 2004-05-11 2005-05-06 Methods and compositions for treating rhinitis
BRPI0510778A BRPI0510778B8 (en) 2004-05-11 2005-05-06 pharmaceutical composition, process for preparing the same, and use of a composition
EA200602092A EA014752B1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
NZ550412A NZ550412A (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
PCT/GB2005/001758 WO2005107711A2 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
EP05742190A EP1771155B1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
PL05742190T PL1771155T3 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
AU2005239866A AU2005239866B2 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
RS20120246A RS52311B (en) 2004-05-11 2005-05-06 PROCEDURE AND COMPOSITION FOR TREATMENT OF RINITIS
ZA200608407A ZA200608407B (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
CN201310132640.3A CN103271910B (en) 2004-05-11 2005-05-06 Treat the method and composition of rhinitis
HRP20120484TT HRP20120484T1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
NO20064521A NO335840B1 (en) 2004-05-11 2006-10-05 Composition for the treatment of rhinitis and the use and process of preparing the same
IL179012A IL179012A (en) 2004-05-11 2006-11-02 Pharmaceutical composition comprising citerizine for the treatment of rhinitis, process for its preparation and uses thereof
US13/444,381 US9980959B2 (en) 2004-05-11 2012-04-11 Method and composition for treating rhinitis
CY20121100541T CY1112981T1 (en) 2004-05-11 2012-06-13 METHOD AND COMPOSITION FOR THE EDUCATION OF RHINIDA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/842,433 US20050255154A1 (en) 2004-05-11 2004-05-11 Method and composition for treating rhinitis

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/571,330 Continuation-In-Part US20070026058A1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
PCT/GB2005/001758 Continuation-In-Part WO2005107711A2 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
US11/571,330 Continuation-In-Part US7385214B2 (en) 2004-07-06 2005-07-04 System and method for correcting systematic error of, and calibrating for, tilt angle of surface topology sensor head having plurality of distance sensors

Publications (1)

Publication Number Publication Date
US20050255154A1 true US20050255154A1 (en) 2005-11-17

Family

ID=34968224

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/842,433 Abandoned US20050255154A1 (en) 2004-05-11 2004-05-11 Method and composition for treating rhinitis
US10/571,330 Abandoned US20070026058A1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
US13/444,381 Active 2026-02-26 US9980959B2 (en) 2004-05-11 2012-04-11 Method and composition for treating rhinitis

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/571,330 Abandoned US20070026058A1 (en) 2004-05-11 2005-05-06 Method and composition for treating rhinitis
US13/444,381 Active 2026-02-26 US9980959B2 (en) 2004-05-11 2012-04-11 Method and composition for treating rhinitis

Country Status (24)

Country Link
US (3) US20050255154A1 (en)
EP (1) EP1771155B1 (en)
JP (1) JP4976283B2 (en)
CN (2) CN103271910B (en)
AT (1) ATE550015T1 (en)
AU (1) AU2005239866B2 (en)
BR (1) BRPI0510778B8 (en)
CA (1) CA2536728C (en)
CY (1) CY1112981T1 (en)
DK (1) DK1771155T3 (en)
EA (1) EA014752B1 (en)
ES (1) ES2395130T3 (en)
HR (1) HRP20120484T1 (en)
IL (1) IL179012A (en)
ME (1) ME01436B (en)
MX (1) MXPA06013121A (en)
NO (1) NO335840B1 (en)
NZ (1) NZ550412A (en)
PL (1) PL1771155T3 (en)
PT (1) PT1771155E (en)
RS (1) RS52311B (en)
SI (1) SI1771155T1 (en)
WO (1) WO2005107711A2 (en)
ZA (1) ZA200608407B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
US10958438B2 (en) * 2018-10-31 2021-03-23 Advanced New Technologies Co., Ltd. Method, apparatus, and electronic device for blockchain-based recordkeeping
CN114392235A (en) * 2022-01-28 2022-04-26 成都大学 Ophthalmic cetirizine hydrochloride liposome, in-situ gel and preparation method thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060484A1 (en) 2004-07-14 2006-07-06 Ucb Farchim Sa LIQUID PHARMACEUTICAL PREPARATIONS CONTAINING A BENZHYDRIL PIPERIZINE COMPOUND
NZ563373A (en) 2005-06-09 2012-06-29 Meda Ab Method and composition for treating inflammatory disorders
FR2900576B1 (en) * 2006-05-03 2008-09-19 Centre Nat Rech Scient PROCESS FOR EXTEMPORANEOUS AND REVERSIBLE CONCENTRATION OF LIPOSOMES.
ATE554775T1 (en) * 2007-11-16 2012-05-15 Baylor College Medicine PHOSPHOLIPID COMPOSITIONS AND USES THEREOF
EP2296711A2 (en) * 2008-05-29 2011-03-23 MDRNA, Inc. Multi-arm amines and uses thereof
WO2010107689A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8524692B2 (en) * 2010-04-29 2013-09-03 Georgia Health Sciences University Research Institute, Inc. Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof
WO2012013566A1 (en) * 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
CN102525921B (en) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2',6,6'-tetraisopropyl-4,4'-bigeminy phenol lipid microsphere preparation and preparation method thereof
KR101475776B1 (en) * 2012-08-24 2014-12-24 영진약품공업 주식회사 Stable composition for skin external application comprising disaturated phospholipids
CN104887635B (en) * 2015-05-20 2019-06-11 苏州东瑞制药有限公司 A kind of Cetirizine hydrochloride Tablets and its preparation process
WO2021089581A1 (en) * 2019-11-04 2021-05-14 Universitat Autonoma De Barcelona Tooth whitening composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US6022561A (en) * 1994-02-04 2000-02-08 Scotia Lipidteknik Ab Bilayers preparations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
GB8522964D0 (en) 1985-09-17 1985-10-23 Biocompatibles Ltd Aerosol
WO1987007506A1 (en) 1986-06-12 1987-12-17 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
DE3778972D1 (en) 1986-06-12 1992-06-17 Liposome Co Inc MEDIUM USING LIPOSOME-ENCLOSED, NON-TEROIDER, ANTI-INFLAMMATORY MEDICINAL PRODUCTS.
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
SE8603812D0 (en) 1986-09-12 1986-09-12 Draco Ab ADMINISTRATION OF LIPOSOMES TO MAMMALS
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
CA2056435A1 (en) 1989-05-15 1990-11-16 Thomas D. Madden Accumulation of drugs into liposomes by a proton gradient
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
CA2120197A1 (en) * 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
BR9408072A (en) * 1993-11-16 1997-08-12 Depotech Corp Vesicles with controlled release of assets
DE4341472A1 (en) 1993-12-02 1995-06-08 Schering Ag A method for increasing the stability of liposome suspensions containing hydrophilic drugs
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
CN1160398A (en) * 1994-09-23 1997-09-24 阿瑞斯药物公司 Compositions and methods for treating mast-cell inflammatory condition
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
AU3153797A (en) 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
BR9809022A (en) 1997-04-30 2000-08-01 Warner Lambert Co Topical nasal anti-inflammatory compositions
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
JP2002507917A (en) * 1997-07-04 2002-03-12 トルサナ オステオポロシス ダイアグノスティクス アクティーゼルスカブ Methods for assessing vertebrate bone quality or skeletal status
EE200100342A (en) * 1998-12-23 2002-10-15 Idea Ag Improved dosage form for non-invasive topical application in vivo
GR1003359B (en) 1998-12-24 2000-04-10 �.�. ����������� �.�.�.�. Liposomic niflumic acid-new transdermal anti-inflammatory medicine
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
WO2001082892A2 (en) * 2000-05-02 2001-11-08 Pharmacept Gmbh Liposomes containing active substances
CA2430897C (en) 2000-12-07 2010-11-16 Universiteit Utrecht Holding B.V. Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders
US20030144336A1 (en) * 2001-08-27 2003-07-31 Pfizer Inc. Method of selecting nonsedating H1-antagonists
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
KR20050044550A (en) 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 Use of an h1 antagonist and a safe steroid to treat rhinitis
AU2003252187A1 (en) 2002-05-15 2003-12-02 Engelbrecht, Edna Topical composition for the treatment of inflammatory conditions of the skin
EP1371362A1 (en) 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
WO2004012675A2 (en) * 2002-08-02 2004-02-12 University Of Massachusetts Lipid binding molecules and methods of use
JP2004168709A (en) * 2002-11-20 2004-06-17 Nidek Co Ltd Antiallergic composition for instillation or rhinenchysis
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
US20080063699A1 (en) 2003-10-15 2008-03-13 Michael Teifel Method of Administering Cationic Liposomes Comprising an Active Drug
JP2005170923A (en) * 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc Liposome-containing X-ray contrast medium and method for producing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US6022561A (en) * 1994-02-04 2000-02-08 Scotia Lipidteknik Ab Bilayers preparations

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090269393A1 (en) * 2006-06-12 2009-10-29 Jubliant Organosys Limited Chewable Bilayer Tablet Formulation
US10958438B2 (en) * 2018-10-31 2021-03-23 Advanced New Technologies Co., Ltd. Method, apparatus, and electronic device for blockchain-based recordkeeping
US11258612B2 (en) 2018-10-31 2022-02-22 Advanced New Technologies Co., Ltd. Method, apparatus, and electronic device for blockchain-based recordkeeping
CN114392235A (en) * 2022-01-28 2022-04-26 成都大学 Ophthalmic cetirizine hydrochloride liposome, in-situ gel and preparation method thereof

Also Published As

Publication number Publication date
ME01436B (en) 2012-12-31
PT1771155E (en) 2012-05-15
CN103271910A (en) 2013-09-04
EA014752B1 (en) 2011-02-28
HK1098960A1 (en) 2007-08-03
MXPA06013121A (en) 2007-05-16
PL1771155T3 (en) 2012-08-31
EA200602092A1 (en) 2007-06-29
US9980959B2 (en) 2018-05-29
NZ550412A (en) 2010-08-27
CA2536728C (en) 2011-02-01
AU2005239866A1 (en) 2005-11-17
JP4976283B2 (en) 2012-07-18
WO2005107711A2 (en) 2005-11-17
BRPI0510778B8 (en) 2021-05-25
SI1771155T1 (en) 2012-09-28
BRPI0510778A (en) 2007-11-20
CN103271910B (en) 2018-11-06
CY1112981T1 (en) 2016-04-13
US20180104238A9 (en) 2018-04-19
IL179012A (en) 2014-11-30
NO335840B1 (en) 2015-03-02
HRP20120484T1 (en) 2012-07-31
ZA200608407B (en) 2007-12-27
JP2007537220A (en) 2007-12-20
EP1771155B1 (en) 2012-03-21
CN1984643A (en) 2007-06-20
ES2395130T3 (en) 2013-02-08
RS52311B (en) 2012-12-31
BRPI0510778B1 (en) 2020-03-10
EP1771155A2 (en) 2007-04-11
DK1771155T3 (en) 2012-07-09
CA2536728A1 (en) 2005-11-17
AU2005239866B2 (en) 2010-03-04
US20130039969A1 (en) 2013-02-14
US20070026058A1 (en) 2007-02-01
WO2005107711A3 (en) 2006-03-16
NO20064521L (en) 2007-02-06
IL179012A0 (en) 2007-03-08
ATE550015T1 (en) 2012-04-15

Similar Documents

Publication Publication Date Title
US9980959B2 (en) Method and composition for treating rhinitis
CA2616515C (en) Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
EP1888033B1 (en) Method and composition for treating inflammatory disorders
ES2315485T3 (en) FORMULATION UNDERSTANDING BUPRENORFINA.
JP5514098B2 (en) Lips for reaching the posterior segment and pharmaceutical compositions for posterior segment diseases
KR101198201B1 (en) Method and composition for treating rhinitis
HK1098960B (en) Method and composition for treating rhinitis
HK1115314B (en) Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
HK1111884B (en) Method and composition for treating inflammatory disorders

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOLIPOX AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PERESWETOFF-MORATH, LENA;CARLSSON, ANDERS;REEL/FRAME:015329/0864

Effective date: 20040509

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION